RNAC
Cartesian Therapeutics, Inc.Company with tickers: RNAC
CIK
1453687
CUSIP
816212302
Shares Outstanding
29,381,514
13F Activity (30d)
75 filings
73 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $1,100,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| Revenue (ASC 606) | $400,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $22,989,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| Research & Development | $14,674,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| Operating Income | $-21,889,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| Net Income | $-17,710,000 | USD | 2025-03-31 | 10-Q | 2026-04-30 |
| EPS (Basic) | $-0.68 | USD/shares | 2025-03-31 | 10-Q | 2026-04-30 |
| EPS (Diluted) | $-0.68 | USD/shares | 2025-03-31 | 10-Q | 2026-04-30 |